ARTICLE | Product Development
With De Backer on board, Vir shares views on partnerships, prophylaxis
Vir’s new CEO thinks its prophylactic influenza mAb, due to read out mid-year, could be a ‘day one solution’ for a flu pandemic
April 4, 2023 7:56 PM UTC
As Marianne de Backer begins her tenure as CEO of seven-year-old Vir, she sees partnership as crucial for keeping up with the speed of innovation and complexity of infectious diseases, and thinks the company’s broadly neutralizing influenza mAb could be a bulwark against the next pandemic.
The former Bayer AG (Xetra:BAYN) pharmaceutical strategy and business development executive arrives at a potentially transformative moment for Vir Biotechnology Inc. (NASDAQ:VIR), which has put mAbs on the market for COVID-19 and Ebola virus, and is slated to see three Phase II readouts this year, including for the prophylactic, intramuscular influenza A mAb VIR-2482. ...
BCIQ Company Profiles